Life Sciences Investing: Pioneer Group Reinvests in Biotech Firm NuVisionSteve Jarvis2023-07-24T13:55:07+01:00March 9th, 2023|Accelerator, BioCity Nottingham, Investment, News|
New Platform Set to Accelerate Early-Stage Targeted Protein Degradation ProgrammesVicky Coghlan2023-06-27T09:55:06+01:00March 7th, 2023|Article, BioCity Nottingham, News|
Pioneer Group Announce Lead Investment in Selentus ScienceVicky Coghlan2023-02-10T10:37:09+00:00February 7th, 2023|BioCity Nottingham, Investment, News|
Nottingham Marketing Pro joins V FormationGemma Cann2022-07-29T11:41:06+01:00July 29th, 2022|BioCity Nottingham, News|
Platelet Services Doubles Lab Footprint at BioCity NottinghamGemma Cann2022-07-04T15:36:00+01:00July 4th, 2022|BioCity Nottingham, News|
Upperton Pharma Solutions Announces £15m Investment in New FacilitiesGemma Cann2022-06-30T11:25:49+01:00May 23rd, 2022|BioCity Nottingham, News|
Reach Separations Marks 10th Birthday Milestone with Further Expansion into EuropeGemma Cann2022-07-28T15:48:05+01:00May 17th, 2022|BioCity Nottingham, News|
Sygnature Discovery Acquires Peak ProteinsGemma Cann2022-06-30T11:28:07+01:00April 28th, 2022|BioCity Nottingham, News|
OMass Therapeutics Raises $100 million to Progress Drug Pipeline in Immunology and Rare DiseasesGemma Cann2022-06-30T11:29:35+01:00April 28th, 2022|BioCity Nottingham, News|
Milestone Anniversary ‘A Proud Landmark’ for V Formation’s DirectorsGemma Cann2022-06-30T12:08:27+01:00April 26th, 2022|BioCity Nottingham, News|